CONFERENCE REPORT

ASCO 2011: Dr. Antoni Ribas Discusses the Impact of 2 New Drugs for the Treatment of Metastatic Melanoma

Interviewed by the editors of ONCOLOGY | August 19, 2011

Dr. Antoni Ribas, UCLA's Jonsson Comprehensive Cancer Center and a presenter at this year's annual meeting of the American Society of Clinical Oncology, discusses the impact of 2 new drugs— ipilimumab (Yervoy) and vemurafenib (Zelboraf)—for the treatment of metastatic melanoma.

ASCO 2011

ASCO 2011: Cytoreductive Surgery plus HIPEC for Metastatic Colon Cancer
October 3, 2011

ASCO 2011: Ramaswami Govindan Discusses Current and Upcoming Lung Cancer Research
August 29, 2011

ASCO 2011: Dr. Antoni Ribas Discusses the Impact of 2 New Drugs for the Treatment of Metastatic Melanoma
August 19, 2011

ASCO 2011: Steve Joffe Discusses Controversies in Phase I Clinical Trials
August 12, 2011

ASCO 2011: Nancy Dawson Discusses Screening for PSA in Prostate Cancer
August 5, 2011

PUBLICATIONS


ONCOLOGY	ONCOLOGY: Nurse Edition	CANCER MANAGEMENT: A Multidisciplinary Approach

TOPIC INDEX

Cancer Types
Breast Breast (HER2+) Breast (Triple-Negative) CML Colorectal Gastrointestinal GIST Genitourinary Gynecologic Head & Neck	Hematology Kidney (Renal Cell) Leukemia Lung Lymphoma Melanoma Multiple Myeloma Ovarian Prostate Sarcoma
Supportive Care	More Topics
Bone Metastases End-of-Life Care Palliative Care	Ethics in Oncology Practice Management Practice & Policy

All Topics

ASCO 2011: Dr. Antoni Ribas Discusses the Impact of 2 New Drugs for the Treatment of Metastatic Melanoma

Join the Conversation